首页> 外文期刊>Current problems in dermatology >Therapies for childhood psoriasis.
【24h】

Therapies for childhood psoriasis.

机译:儿童牛皮癣的治疗方法。

获取原文
获取原文并翻译 | 示例
           

摘要

With a prevalence of 2% of the general population of Europe and North America, psoriasis represents one of the most common and significant dermatologic disorders. While it has been claimed that psoriasis is uncommon in children, in fact 27% of cases manifest before the age of 16 years; moreover, psoriasis represents 4.1% of all dermatoses seen in children under the age of 16 years. Both recognition and treatment of psoriasis in children represent unique challenges. Early diagnosis and appropriate management are particularly important in children to lessen long-term disease-related psychosocial problems and comorbidities. Psoriasis in childhood is a disease of many forms, which may change over time. It may be difficult to recognize, since the frequencies of some types of patterns of psoriasis differ between adults and children, and some clinical features are distinctive to the pediatric age group. Management involves education of the child and parents concerning the nature of the disease and the effects of treatment. Environmental triggers should be sought and eliminated, particularly infection, trauma, and stress. The treatment options available are basically the same as for adults, but special care should be taken in order not to endanger the development or the future health of the child. In children, treatment modalities are limited because of safety concerns and/or poor compliance associated with messy and time-consuming therapies. Randomized controlled clinical trials involving children under the age of 12 years suffering from psoriasis have been reported only for 2 topical treatments, namely, calcipotriol and corticosteroids. Phototherapy and systemic therapy with methotrexate, acitretin and cyclosporin have limited use because of lower tolerability in children and cumulative toxicities. For this reason, treatments of psoriasis with the newer biologic agents, particularly the soluble tumor necrosis factor receptor fusion protein etanercept, are emerging. Finally, it is important to acknowledge that topical and systemic treatments are only part of a 'total care' package combining treatment, disease-specific education, and psychological support to cope with a possible lifelong skin condition.
机译:银屑病是欧洲和北美总人口的2%,是最常见和最重要的皮肤病之一。虽然据称儿童银屑病并不常见,但实际上27%的病例在16岁之前就已经表现出来。此外,牛皮癣占16岁以下儿童中所有皮肤病的4.1%。对儿童牛皮癣的认识和治疗都代表着独特的挑战。对儿童而言,早期诊断和适当管理对减轻长期疾病相关的心理社会问题和合并症尤其重要。儿童期牛皮癣是多种形式的疾病,可能会随着时间而改变。由于某些类型的牛皮癣模式的频率在成人和儿童之间是不同的,并且某些临床特征对于小儿年龄段来说是独特的,因此可能难以识别。管理包括对孩子和父母进行有关疾病性质和治疗效果的教育。应寻找并消除环境诱因,尤其是感染,创伤和压力。可用的治疗选择与成人基本相同,但应特别注意以免危及儿童的成长或未来健康。在儿童中,由于安全方面的考虑和/或与混乱且费时的疗法相关的依从性差,治疗方式受到限制。据报道,涉及牛皮癣的12岁以下儿童的随机对照临床试验仅针对两种局部治疗方法,即卡泊三醇和皮质类固醇。甲氨蝶呤,阿维A和环孢菌素的光疗和全身治疗由于对儿童的耐受性较低和累积毒性而使用有限。由于这个原因,出现了用新型生物制剂,特别是可溶性肿瘤坏死因子受体融合蛋白依那西普治疗牛皮癣的方法。最后,必须承认局部和全身治疗只是“全面护理”计划的一部分,该计划将治疗,针对特定疾病的教育以及心理支持相结合,以应对可能的终身皮肤状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号